Selected mosquito-borne illnesses—Chikungunya

McFee, Robin B.

doi:10.1016/j.disamonth.2018.01.009

Cited by 7 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chikungunya fever is caused by Chikungunya virus (CHIKV), an arbovirus that belongs to the genus Alphavirus and is transmitted by Aedes mosquitoes. The most common symptoms are fever, asthenia, arthralgia, myalgia, headache and rash [1, 2] and even though it is a self-limiting disease, it can last from days to years thus posing a significant impact in public health and serious economic burden [3].…”

mentioning

confidence: 99%

Detection of East/Central/South African genotype Chikungunya virus during an outbreak in a southeastern state of Brazil

et al. 2018

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) is an arbovirus transmitted by Aedes mosquitoes that was first identified in Brazil in 2014. It causes a febrile illness characterised by severe arthralgia and rash. Our group investigated a suspected CHIKV outbreak in Governador Valadares, state of Minas Gerais, Brazil and from 25 acute-phase patients, 10 had qRT-PCR positive sera samples and had E1 partial sequence amplified and Sanger sequenced. Samples were identified as East/Central/South African (ECSA) genotype by phylogenetic analysis and clustered with CHIKV sequences isolated in the neighbour state of Bahia. Our findings confirm previous predictions that ECSA genotype would spread through northeast and southeast of Brazil.

show abstract

mentioning

confidence: 99%

Detection of East/Central/South African genotype Chikungunya virus during an outbreak in a southeastern state of Brazil

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Foi descrito melhora significativa nos sintomas associados à tenossinovite e à poliartrite. Além disso, a prednisona em baixa dose forneceu, meses após a doença aguda, maior capacidade de deambulação (MCFEE, 2018). Os anti-inflamatórios não esteroides podem reduzir a dor em até 24 semanas de tratamento, mas o impacto residual a longo prazo após a interrupção do tratamento não foi avaliado (RODRIGO et al, 2022).…”

Section: Resultsunclassified

Tratamento Da Artralgia Crônica Na Chikungunya: Uma Revisão Integrativa

Guimarães,

Martins,

Bezerra

et al. 2024

Rev. Foco

View full text Add to dashboard Cite

Objetivos: este estudo propõe-se a identificar, por meio de uma revisão integrativa, quais as possibilidades de tratamento da dor crônica decorrente da chikungunya, bem como sua eficácia. Métodos: a pesquisa foi realizada nas bases de dados da BVS, Scielo e PubMed utilizando os descritores “tratamento and artralgia and chikungunya”, através dos filtros da própria base de dados, estabeleceu-se os seguintes critérios de inclusão: artigos publicados nos últimos 5 anos e com acesso ao texto completo gratuitamente. Resultados: foram obtidos 11 artigos como amostra final após aplicados os critérios de inclusão e exclusão, os quais mostraram propostas terapêuticas não farmacológicas como fisioterapia, neuromodulação por estimulação transcraniana por corrente contínua e homeopatia. Dentre as terapias farmacológicas, foi recomendado: o uso de anti-inflamatórios na fase crônica; vários artigos expuseram estudos com drogas modificadoras de doença reumática; estudos pré-clínicos de drogas com resultados eficazes como o abatacept associado ao anticorpo anti-chikungunya, bindarit, sofosbuvir, fingolimod, o pentosano polissulfato sódico, ribavirina e uma formulação poliherbal indiana composta por Withania somnifera. Conclusão: Os novos estudos apesar de incipientes, parecem promissores e futuramente teremos mais opções de tratamentos eficazes e acessíveis para o manejo adequado da dor associada ao processo inflamatório crônico pós-chikungunya.

show abstract

“…In MAC‐ELISA, CHIK VL is generally used as an antigen that binds specific IgM to be detected. However, obtaining viral lysate is time‐consuming and requires that experiments be conducted in a Biosafety Level‐3 laboratory . Before any use, the virus must be inactivated using chemical treatment such as β‐propiolactone (BPL) .…”

Section: Discussionmentioning

confidence: 99%

“…However, obtaining viral lysate is time-consuming and requires that experiments be conducted in a Biosafety Level-3 laboratory. 58 Before any use, the virus must be inactivated using chemical treatment such as β-propiolactone (BPL). 59 It is generally recognized that BPL inactivates viruses through cross-linking of viral surface proteins.…”

Section: Discussionmentioning

confidence: 99%

Detection of chikungunya virus‐specific IgM on laser‐cut paper‐based device using pseudo‐particles as capture antigen

Theillet

Grard

Galla

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

The incidence of arbovirus infections has increased dramatically in recent decades, affecting hundreds of millions of people each year. The Togaviridae family includes the chikungunya virus (CHIKV), which is typically transmitted by Aedes mosquitoes and causes a wide range of symptoms from flu‐like fever to severe arthralgia. Although conventional diagnostic tests can provide early diagnosis of CHIKV infections, access to these tests is often limited in developing countries. Consequently, there is an urgent need to develop efficient, affordable, simple, rapid, and robust diagnostic tools that can be used in point‐of‐care settings. Early diagnosis is crucial to improve patient management and to reduce the risk of complications. A glass‐fiber laser‐cut microfluidic device (paper‐based analytical device [PAD]) was designed and evaluated in a proof of principle context, for the analysis of 30 µL of patient serum. Biological raw materials used for the functionalization of the PAD were first screened by MAC‐ELISA (IgM capture enzyme‐linked immunosorbent assay) for CHIKV Immunoglobulin M (IgM) capture and then evaluated on the PAD using various human samples. Compared with viral lysate traditionally used for chikungunya (CHIK) serology, CHIKV pseudo‐particles (PPs) have proven to be powerful antigens for specific IgM capture. The PAD was able to detect CHIKV IgM in human sera in less than 10 minutes. Results obtained in patient sera showed a sensitivity of 70.6% and a specificity of around 98%. The PAD showed few cross‐reactions with other tropical viral diseases. The PAD could help health workers in the early diagnosis of tropical diseases such as CHIK, which require specific management protocols in at‐risk populations.

show abstract

Selected mosquito-borne illnesses—Chikungunya

Cited by 7 publications

References 35 publications

Detection of East/Central/South African genotype Chikungunya virus during an outbreak in a southeastern state of Brazil

Detection of East/Central/South African genotype Chikungunya virus during an outbreak in a southeastern state of Brazil

Tratamento Da Artralgia Crônica Na Chikungunya: Uma Revisão Integrativa

Detection of chikungunya virus‐specific IgM on laser‐cut paper‐based device using pseudo‐particles as capture antigen

Contact Info

Product

Resources

About